ANTICOLINÉRGICO
Glicopirronio (glicopirrolato)
Ficha de consulta para farmacia hospitalaria: indicaciones, preparación, dilución, estabilidad y compatibilidad de glicopirronio (glicopirrolato), con la fuente oficial de cada dato.
También conocido como: glicopirronio, glycopyrronium, Glicopirrolato, Robinul
Presentación
Solución 0.2 mg/mL — documentado: Meitheal (FDA)
| Producto de referencia | Titular | Vía | Fuente |
|---|---|---|---|
| Glycopyrrolate | Meitheal Pharmaceuticals Inc. | Intramuscular, Intravenous | FDA (DailyMed) |
| Glycopyrrolate | Meitheal Pharmaceuticals Inc. | Intramuscular, Intravenous | FDA (DailyMed) |
¿Para qué sirve glicopirronio (glicopirrolato)? Indicaciones autorizadas
1 INDICATIONS AND USAGE Glycopyrrolate Injection is an anticholinergic indicated: in anesthesia (adult and pediatric patients) for reduction of salivary, tracheobronchial, and pharyngeal secretions, reduction of volume and acidity of gastric secretions, and blockade of cardiac inhibitory reflexes during induction of anesthesia and intubation. intraoperatively to counteract surgically or drug-induced or vagal…
FDA (DailyMed) · Glycopyrrolate · Indications and usage · texto original en inglésLeer la sección completa
1 INDICATIONS AND USAGE Glycopyrrolate Injection is an anticholinergic indicated: in anesthesia (adult and pediatric patients) for reduction of salivary, tracheobronchial, and pharyngeal secretions, reduction of volume and acidity of gastric secretions, and blockade of cardiac inhibitory reflexes during induction of anesthesia and intubation. intraoperatively to counteract surgically or drug-induced or vagal reflex-associated arrhythmias. for protection against peripheral muscarinic effects of cholinergic agents. ( 1 ) in peptic ulcer (adults) To reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer when rapid anticholinergic effect is desired or oral medication is not tolerated. Limitations of Use Glycopyrrolate Injection is not indicated as monotherapy for the treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established. ( 1 ) 1.1 Preanesthetic Glycopyrrolate Injection is indicated in adults and pediatric patients for reduction of salivary, tracheobronchial, and pharyngeal secretions, reduction of volume and acidity of gastric secretions, and blockade of cardiac inhibitory reflexes during induction of anesthesia and intubation. 1.2 Intraoperative Glycopyrrolate Injection is indicated in adults and pediatric patients to counteract surgically or drug-induced or vagal reflex-associated arrhythmias. 1.3 Reversal of Neuromuscular Blockade Glycopyrrolate Injection is indicated in adults and pediatric patients for protection against peripheral muscarinic effects of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing agents. 1.4 Peptic Ulcer Glycopyrrolate Injection is indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated. Limitations of Use Glycopyrrolate Injection is not indicated as monotherapy for the treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established.
INDICATIONS AND USAGE In Anesthesia Glycopyrrolate Injection is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. When indicated, Glycopyrrolate Injection may be used intraoperatively to counteract…
FDA (DailyMed) · Glycopyrrolate · Indications and usage · texto original en inglésLeer la sección completa
INDICATIONS AND USAGE In Anesthesia Glycopyrrolate Injection is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. When indicated, Glycopyrrolate Injection may be used intraoperatively to counteract surgically or drug-induced or vagal reflexes associated arrhythmias. Glycopyrrolate protects against the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing muscle relaxants. In Peptic Ulcer For use in adults as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated.
Contraindicaciones de glicopirronio (glicopirrolato)
4 CONTRAINDICATIONS Glycopyrrolate injection is contraindicated in: patients with known hypersensitivity to glycopyrrolate injection or any of its inactive ingredients. peptic ulcer patients with the following concurrent conditions: glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal…
FDA (DailyMed) · Glycopyrrolate · Contraindications · texto original en inglésLeer la sección completa
4 CONTRAINDICATIONS Glycopyrrolate injection is contraindicated in: patients with known hypersensitivity to glycopyrrolate injection or any of its inactive ingredients. peptic ulcer patients with the following concurrent conditions: glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus, intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. Known hypersensitivity to glycopyrrolate or any of its inactive ingredients. ( 4 ) Peptic ulcer patients with glaucoma; obstructive uropathy; obstructive disease of the gastrointestinal tract; paralytic ileus, intestinal atony of the elderly, or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon; complicating ulcerative colitis; myasthenia gravis. ( 4 )
CONTRAINDICATIONS Known hypersensitivity to glycopyrrolate or any of its inactive ingredients. In addition, in the management of peptic ulcer patients, because of the longer duration of therapy, glycopyrrolate injection may be contraindicated in patients with the following concurrent conditions: glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus, intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis.
FDA (DailyMed) · Glycopyrrolate · Contraindications · texto original en inglés
Ajuste en insuficiencia renal
In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other therapy. 8.6 Renal Impairment Renal elimination of glycopyrrolate may be significantly reduced in patients with renal failure.
FDA (DailyMed) · Glycopyrrolate · Use in specific populations · texto original en inglés
Ajuste en insuficiencia hepática
Most of the available data are based on studies with exposures that occurred at the time of Cesarean section delivery, and these studies have not identified an adverse effect on maternal outcomes or infant Apgar scores (see Data).
FDA (DailyMed) · Glycopyrrolate · Use in specific populations · texto original en inglés
In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other therapy. 8.6 Renal Impairment Renal elimination of glycopyrrolate may be significantly reduced in patients with renal failure.
FDA (DailyMed) · Glycopyrrolate · Use in specific populations · texto original en inglés
Reconstitución de glicopirronio (glicopirrolato)
No requiere.
Dilución de glicopirronio (glicopirrolato)
No usar Ringer lactato como diluyente.
Administración de glicopirronio (glicopirrolato)
IV o IM.
Compatibilidad de glicopirronio (glicopirrolato)
Compatible con
- SF 0.9%
- Glucosa 5%
Incompatible con
- Ringer lactato
- En jeringa (pH >6): bicarbonato, diazepam, dexametasona, tiopental, metohexital, pentobarbital, cloranfenicol, dimenhidrinato, pentazocina
Conservación y protección de la luz
20–25 °C.
Las fuentes no indican protección de la luz para el producto (el paciente puede presentar fotofobia).
Advertencias
- Se usa con neostigmina para revertir el bloqueo neuromuscular.
Fuentes
- FDA (DailyMed) · Glycopyrrolate InjectionMeitheal Pharmaceuticals Inc. · 0.2 mg/mL · versión 2026-05-20
- FDA (DailyMed) · GlycopyrrolateMeitheal Pharmaceuticals Inc. · 0.2 mg/mL (otra etiqueta de Meitheal) · versión 2023-01-12
Interacciones de glicopirronio (glicopirrolato)
3 medicamentos del catálogo con una interacción documentada en sus fichas oficiales. Abre cada una para ver el efecto, la recomendación y su fuente.
- Bicarbonato de sodioMayor
- DexametasonaMayor
- DiazepamMayor
Identificación
- SNOMED CT (VTM)
- 772943003
- RxNorm
- 1546438
Información de consulta profesional extraída de las fichas técnicas y etiquetas oficiales citadas. Las condiciones de preparación, estabilidad y administración dependen del producto concreto: verifica el documento del producto que utilizas. No sustituye el criterio clínico ni la valoración del paciente.